2009 December 11

New Executive Leadership and CEO Announced for BiPar Sciences

2009 December 11

BiPar Sciences Announces Update on the Clinical Development Progress of BSI-201 for Metastatic Triple-Negative Breast Cancer

2009 July 17

BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer

2009 May 31

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

2009 May 18

BiPar Sciences` Investigational PARP Inhibitor, BSI-201, To Be Highlighted During ASCO`s Plenary Session

2009 April 15

Sanofi-aventis To Acquire BiPar Sciences

2009 February 03

BiPar Sciences to Present At the 11th Annual BIO CEO & Investor Conference in New York City

2009 January 12

BiPar Sciences Raises $20 Million to Advance Clinical Programs

2009 January 07

BiPar Sciences to Present at the 27th Annual JP Morgan Healthcare Conference in San Francisco

2008 December 12

BiPar Sciences Presents Interim Phase 2 Results For PARP Inhibitor BSI-201 at San Antonio Breast Cancer Symposium

2008 December 10

BiPar Sciences Receives 2008 Emerging Technology Award in Biotechnology

2008 December 04

BiPar Sciences to Present at the 31st CTRC-AACR Annual San Antonio Breast Cancer Symposium

2008 October 28

BiPar Sciences' Lead Compound Selected as Top 10 Oncology Drug Candidate

2008 October 21

BiPar to Present at the 7th Annual BIO Investor Forum in San Francisco

2008 September 23

BiPar Sciences Announces Senior Appointments in Corporate Development and Legal Functions

2008 June 02

BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor

2008 May 28

BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, with Phase 2 Trial in Uterine Cancer

2008 May 15

BiPar Sciences Announces Clinical Data on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting

2008 May 08

BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer

2008 April 14

BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies

2008 April 10

BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer

2008 February 14

BiPar names Hoyoung Huh, M.D., PH.D., President and Chief Executive Officer

2007 November 15

BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data

2007 October 25

BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP1 Gene in Multiple Cancer Types

2007 October 24

BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity with BSI-401, its Second-Generation PARP Inhibitor

2007 October 22

BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer

2007 September 25

BiPar Expands Management Team To Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials For Cancer

2007 September 19

BiPar Names G. Kirk Raab Acting Chief Executive Officer

2007 May 17

BiPar Names John Schembri Chief Financial Officer

2007 February 26

BiPar Sciences Raises $35 Million to Advance Pipeline of Novel PARP Inhibitor Cancer Drug Candidates

2007 January 04

BiPar Sciences Begins Enrollment in Phase 1b Study of BSI-201

2006 August 07

BiPar Sciences Co-Founder Allan Basbaum Honored with Membership in Royal Society

2006 June 14

BiPar Sciences Announces $5 Million Financing to Accelerate BSI-201 Clinical Program

2006 March 07

BiPar Sciences Announces Start of Phase 1 Clinical Trial for BSI-201 in Patients With Advanced Cancer; Lead Product Candidate in Clinic Just One Year After Initial Financing Round

2004 December 20

BiPar Sciences Raises $13 Million in Series A Financing